A Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Status:
Recruiting
Trial end date:
2022-06-29
Target enrollment:
Participant gender:
Summary
Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide
in the treatment of secondary hyperparathyroidism (SHPT) in pediatric subjects between ≥ 2 to
< 18 years of age, with chronic kidney disease (CKD) on hemodialysis